Lenbelintide vs MET-233i

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin receptor · full Obesity pipeline

Lenbelintide

Developed by AstraZeneca

Phase 3 in Obesitypeptide
Partial signal

NCT06595238 · Phase 2 · completed

Randomized, quadruple-blind, placebo-controlled Phase 2 trial in 262 participants with obesity or overweight; primary endpoint Percent change in body weight from baseline to week 26. Completed December 2025; numerical results not yet posted to the registry, so the grade is the design ceiling for a completed controlled study without results.

Next expected readout: January 2027 · NCT06151964 (registry estimate)

No aligned efficacy figure on record for this race.

MET-233i

Developed by Pfizer and partners

Phase 1/2 in Obesitypeptide
Weak signal

NCT07022977 · Phase 1 · completed

A randomised, double-blind single- and multiple-ascending-dose Phase 1 study in 144 otherwise healthy adults with obesity or overweight. Its primary endpoint is the occurrence of treatment-emergent adverse events and weight change is only secondary, so it is not efficacy evidence; no results are posted.

Next expected readout: January 2027 · NCT07725809 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLenbelintideMET-233i
Body weight, % change—Trial running · NCT07784270—Not reported
Weight loss of 5% or more—Trial running · NCT07784270—Not reported
Weight loss of 10% or more—Trial running · NCT07784270—Not reported
Waist circumference, change (cm)—Trial running · NCT07784270—Not reported

Body weight, % change

Lenbelintide
—Trial running · NCT07784270
MET-233i
—Not reported

Weight loss of 5% or more

Lenbelintide
—Trial running · NCT07784270
MET-233i
—Not reported

Weight loss of 10% or more

Lenbelintide
—Trial running · NCT07784270
MET-233i
—Not reported

Waist circumference, change (cm)

Lenbelintide
—Trial running · NCT07784270
MET-233i
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Lenbelintide: no structured comparison results are available for Obesity.

MET-233i: no structured comparison results are available for Obesity.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lenbelintide's landscape · MET-233i's landscape